RSS Feeds
Diphosphonate Therapy in a Patient with Myositis Ossificans Progressiva
Abstract
A young man with severe debility from myositis ossificans progressiva was treated with sodium etidronate, a diphosphonate known to reduce the rates of hydroxyapatite formation and dissolution. He showed progressive improvement while receiving therapy. Radiocalcium kinetics and metabolic balance studies documented the reduction of bone mineral accretion and resorption rates. A lack of change in body calcium balance during diphosphonate administration suggests that sodium etidronate can initiate the desired clinical effect without demineralizing skeletal bone.
Article and Author Information
-
▸From the Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md.
-
▸Requests for reprints should be addressed to James M. Phang, M.D., Bldg. 10, Room 4N117, National Institutes of Health, Bethesda, Md. 20014
-
- Received November 9, 1970.
- Accepted December 4, 1970.
